Darolutamide Stands Out in the Pool of 2nd Generation Antiandrogen Therapies

Eleni Efstathiou, MD, PhD, provides background on the ARAMIS trial of darolutamide compared with placebo as treatment of patients with nonmetastatic castration-resistant prostate cancer.

Eleni Efstathiou, MD, PhD, an oncology specialist at the University of Texas MD Anderson Cancer Center provides background on the ARAMIS trial of darolutamide (Nubeqa) compared with placebo as treatment of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Back in 2006, agents like abiraterone acetate (Zytiga), enzalutamide (Xtandi), and apalutamide (Erleada) were being developed, oncologists at the time believed that the field was becoming saturated with antiandrogentherapies. Efstathiou says, that what is interesting about darolutamide, is that it has the ability to cross the blood-brain barrier. This sets darolutamide apart from enzalutamide and apalutamide, especially, because the mechanism of action for these 2 agents are almost identical.

Overall, the profile of darolutamide makes it ideal to help improve quality of life in patients with nmCRPC, Efstathiou explains.